IOP Pattern in Primary Angle Closure and Primary Angle Closure Glaucoma Patients, Before and After LPI
Launched by SENSIMED AG · Jul 19, 2013
Trial Information
Current as of April 29, 2025
Withdrawn
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Diagnosis of Primary Angle Closure (PAC) or Primary Angle Closure Glaucoma (PACG) with indication for Laser Peripheral Iridotomy (LPI). PAC is defined by the presence of a partial or complete iridotrabecular contact(ITC) in more than 2 quadrants with either raised intraocular pressure (IOP) (ie. more than 21 mmHg) and/or PAS; however, with normal optic disc and visual field. PACG is defined by the presence of ITC with either raised IOP and/or PAS, and evidence of glaucomatous optic disc and visual field
- • No IOP-lowering drug treatment or a 4-week wash-out period prior to Study Day 0
- • Aged ≥18 years, of either sex
- • Not more than 6 diopters spherical equivalent on the study eye
- • Have given written informed consent, prior to any investigational procedures
- Exclusion Criteria:
- • History of acute angle closure glaucoma on the study eye
- • Secondary angle closure glaucoma on the study eye
- • History of ocular surgery within the last 3 months on the study eye
- • History of ocular laser treatment, including previous LPI on the study eye
- • Corneal or conjunctival abnormality precluding contact lens adaptation on the study eye
- • Severe dry eye syndrome on the study eye
- • Patients with allergy to corneal anesthetic
- • Patients with contraindications for silicone contact lens wear
- • Patients not able to understand the character and individual consequences of the investigation
About Sensimed Ag
Sensimed AG is a pioneering medical technology company specializing in the development of innovative solutions for the management of ocular diseases, particularly glaucoma. Headquartered in Switzerland, Sensimed is renowned for its cutting-edge wearable sensor technology that enables continuous monitoring of intraocular pressure, providing valuable insights for both patients and healthcare providers. The company's commitment to advancing eye care through research and clinical trials underscores its dedication to improving patient outcomes and enhancing the understanding of chronic eye conditions. With a strong emphasis on collaboration and innovation, Sensimed AG is at the forefront of transforming the landscape of ophthalmic diagnostics and treatment.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Paris, , France
Patients applied
Trial Officials
Christophe Baudouin, MD
Principal Investigator
CHNO des Quinze-Vingts, 28 rue Charenton, 75571 Paris Cedex 12, France
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials